Scholarlink

<p>Accurate molecular subtyping of breast cancer is essential for personalized therapy, yet inconsistencies between biopsy and postoperative immunohistochemistry (IHC) due to tumor heterogeneity and sampling limitations pose clinical challenges. We developed Ultrasound-Guided Pathomic Subtyping (US-GPS), a cross-modal framework enabling subtype prediction using ultrasound (US) alone, guided by IHC-stained whole-slide images (WSIs) during training. A total of 1283 patients from four centers were retrospectively included, with 454 cases (paired US and WSIs) for model training/validation and 829 US-only cases for external testing. US-GPS aligned WSI-derived patch- and region-level features (from HER2, ER, PR, Ki-67 IHC stains) with handcrafted and deep US features via co-attention and contrastive learning. Using US alone, the model achieved an AUROC of 0. 966 (95% CI 0.960–0.991) in internal validation, comparable to pathology-only (0. 971) and joint models (0.980), and superior to US-only (0.861). Performance remained robust across both internal (AUROC range: 0.930–0.942) and all external cohorts (AUROC range: 0.915–0.963). US-GPS enables scalable, non-invasive, and interpretable subtype classification, with potential for both pre-treatment decision-making and longitudinal monitoring of molecular phenotypic shifts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ultrasound-guided deep learning framework with whole slide images for molecular subtyping of breast cancer: a multicentre, retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月22日

查看全文
  • Wei-Jie Zou,
  • Lin-Feng Zheng,
  • Bo-Jian Feng,
  • Jin-Cao Yao,
  • Ying-Xue Wu,
  • Lu-Jiao Lv,
  • Bei Wei,
  • Yin Zheng,
  • Xin-Ying Zhu,
  • Jia-Heng Huang,
  • Tian Jiang,
  • Kai Wang,
  • Shi-Hao Xu,
  • Xiao-Mao Luo,
  • Vicky Yang Wang,
  • Dan Su,
  • Gao-Jun Teng,
  • Dong Xu

摘要

Accurate molecular subtyping of breast cancer is essential for personalized therapy, yet inconsistencies between biopsy and postoperative immunohistochemistry (IHC) due to tumor heterogeneity and sampling limitations pose clinical challenges. We developed Ultrasound-Guided Pathomic Subtyping (US-GPS), a cross-modal framework enabling subtype prediction using ultrasound (US) alone, guided by IHC-stained whole-slide images (WSIs) during training. A total of 1283 patients from four centers were retrospectively included, with 454 cases (paired US and WSIs) for model training/validation and 829 US-only cases for external testing. US-GPS aligned WSI-derived patch- and region-level features (from HER2, ER, PR, Ki-67 IHC stains) with handcrafted and deep US features via co-attention and contrastive learning. Using US alone, the model achieved an AUROC of 0. 966 (95% CI 0.960–0.991) in internal validation, comparable to pathology-only (0. 971) and joint models (0.980), and superior to US-only (0.861). Performance remained robust across both internal (AUROC range: 0.930–0.942) and all external cohorts (AUROC range: 0.915–0.963). US-GPS enables scalable, non-invasive, and interpretable subtype classification, with potential for both pre-treatment decision-making and longitudinal monitoring of molecular phenotypic shifts.